Biogen Wants Kyle Bass To Give Up Financial Docs At PTAB

Law360, New York (July 9, 2015, 9:10 PM EDT) -- An organization tied to superstar hedge fund head Kyle Bass should release a set of financial documents that will help determine whether he is abusing the America Invents Act process by shorting stocks as he challenges patents, Biogen International GmbH has urged the Patent Trial and Appeal Board.

Biogen argues that Bass is on a mission to encourage PTAB to invalidate drug-related patents, including two patents related to its multiple sclerosis drug Tecfidera, as part of a larger strategy to make money by shorting the stocks...
To view the full article, register now.